These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8473885)

  • 1. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives.
    Francis PT; Sims NR; Procter AW; Bowen DM
    J Neurochem; 1993 May; 60(5):1589-604. PubMed ID: 8473885
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurotransmitters and second messengers in aging and Alzheimer's disease.
    Francis PT; Webster MT; Chessell IP; Holmes C; Stratmann GC; Procter AW; Cross AJ; Green AR; Bowen DM
    Ann N Y Acad Sci; 1993 Sep; 695():19-26. PubMed ID: 7902054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease.
    Simpkins JW; Singh M; Bishop J
    Neurobiol Aging; 1994; 15 Suppl 2():S195-7. PubMed ID: 7700453
    [No Abstract]   [Full Text] [Related]  

  • 4. Glutamatergic abnormalities in Alzheimer's disease and a rationale for clinical trials with L-glutamate.
    Deutsch SI; Morihisa JM
    Clin Neuropharmacol; 1988 Feb; 11(1):18-35. PubMed ID: 3280127
    [No Abstract]   [Full Text] [Related]  

  • 5. Alzheimer's disease in a patient with posterior cortical atrophy.
    Berthier ML; Leiguarda R; Starkstein SE; Sevlever G; Taratuto AL
    J Neurol Neurosurg Psychiatry; 1991 Dec; 54(12):1110-1. PubMed ID: 1783928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microanatomical correlates of cognitive ability and decline: normal ageing, MCI, and Alzheimer's disease.
    Chance SA; Clover L; Cousijn H; Currah L; Pettingill R; Esiri MM
    Cereb Cortex; 2011 Aug; 21(8):1870-8. PubMed ID: 21239393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Life and death of neurons in the aging cerebral cortex.
    Morrison JH; Hof PR
    Int Rev Neurobiol; 2007; 81():41-57. PubMed ID: 17433917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Excitatory amino acids, the cerebral cortex and aging: a new perspective].
    Mora F
    An R Acad Nac Med (Madr); 1991; 108(4):701-10. PubMed ID: 1688036
    [No Abstract]   [Full Text] [Related]  

  • 9. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
    Yew B; Nation DA;
    Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neural substrates of cognitive and behavioral deficits in atypical Alzheimer's disease.
    von Gunten A; Bouras C; Kövari E; Giannakopoulos P; Hof PR
    Brain Res Rev; 2006 Aug; 51(2):176-211. PubMed ID: 16413610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ratio of pyramidal cells versus non-pyramidal cells in the human frontal isocortex and changes in ratio with ageing and Alzheimer's disease.
    Braak H; Braak E
    Prog Brain Res; 1986; 70():185-212. PubMed ID: 3575748
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial (Thematic Issue: Endocrine Disorders and Cognitive Function in the Elderly).
    Pasqualetti G; Calsolaro V; Monzani F
    Recent Pat Endocr Metab Immune Drug Discov; 2016; 10(1):2-3. PubMed ID: 27981913
    [No Abstract]   [Full Text] [Related]  

  • 13. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: I. Superior frontal and inferior temporal cortex.
    Hof PR; Cox K; Morrison JH
    J Comp Neurol; 1990 Nov; 301(1):44-54. PubMed ID: 2127598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What are we seeing? Is posterior cortical atrophy just Alzheimer disease?
    Tang-Wai D; Mapstone M
    Neurology; 2006 Feb; 66(3):300-1. PubMed ID: 16476924
    [No Abstract]   [Full Text] [Related]  

  • 15. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamatergic systems in Alzheimer's disease.
    Francis PT
    Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S15-21. PubMed ID: 12973746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive supranuclear palsy with dementia: cortical pathology.
    Bigio EH; Brown DF; White CL
    J Neuropathol Exp Neurol; 1999 Apr; 58(4):359-64. PubMed ID: 10218631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive degeneration of nonphosphorylated neurofilament protein-enriched pyramidal neurons predicts cognitive impairment in Alzheimer's disease: stereologic analysis of prefrontal cortex area 9.
    Bussière T; Giannakopoulos P; Bouras C; Perl DP; Morrison JH; Hof PR
    J Comp Neurol; 2003 Aug; 463(3):281-302. PubMed ID: 12820162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia.
    Du AT; Schuff N; Kramer JH; Rosen HJ; Gorno-Tempini ML; Rankin K; Miller BL; Weiner MW
    Brain; 2007 Apr; 130(Pt 4):1159-66. PubMed ID: 17353226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment strategy for the corticocortical neuron pathology of Alzheimer's disease.
    Bowen DM; Francis PT; Procter AW; Halliwell JV; Mann DM; Neary D
    Ann Neurol; 1992 Jul; 32(1):112. PubMed ID: 1642465
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.